Development and Evaluation of an Improved Methodology for Assessing Adherence to Evidence-Based Drug Therapy Guidelines Using Claims Data

Non-adherence to evidence-based pharmacotherapy is associated with increased morbidity and mortality. Claims data can be used to detect and intervene on such non-adherence, but existing claims-based approaches for measuring adherence to pharmacotherapy guidelines have significant limitations. In this manuscript, we describe a methodology for assessing adherence to pharmacotherapy guidelines that overcomes many of these limitations. To develop this methodology, we first reviewed the literature to identify prior work on potential strategies for overcoming these limitations. We then assembled a team of relevant domain experts to iteratively develop an improved methodology. This development process was informed by the use of the proposed methodology to assess adherence levels for 14 pharmacotherapy guidelines related to seven common diseases among approximately 36,000 Medicaid beneficiaries. Finally, we evaluated the ability of the methodology to overcome the targeted limitations. Based on this evaluation, we conclude that the proposed methodology overcomes many of the limitations associated with existing approaches.

[1]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[2]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[3]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[4]  D. Share,et al.  Costs and utilization associated with pharmaceutical adherence in a diabetic population. , 2004, The American journal of managed care.

[5]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[6]  Harlan M Krumholz,et al.  National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. , 2003, Archives of internal medicine.

[7]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .

[8]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[9]  L L Roos,et al.  Estimating the burden of disease. Comparing administrative data and self-reports. , 1997, Medical care.

[10]  M. Cheang,et al.  Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.

[11]  K. Chan,et al.  Methods for evaluation of medication adherence and persistence using automated databases , 2006, Pharmacoepidemiology and drug safety.

[12]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[13]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[14]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[15]  Bin Nan,et al.  Limits of the HEDIS Criteria in Determining Asthma Severity for Children , 2004, Pediatrics.

[16]  S. Morgan,et al.  Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. , 2006, Clinical therapeutics.